Baseline characteristics of included patients, stratified by diagnosis
| Rheumatoid arthritis* n=8168 | Psoriatic arthritis* n=2068 | Axial spondyloarthritis* n=1758 | Other* n=795 | Total n=12 789 | ||
| Gender, n (%) | Female | 5814 (71) | 1194 (58) | 811 (46) | 547 (69) | 8366 (65) |
| Age, years, n (%) | ≤39 | 349 (4) | 143 (7) | 361 (21) | 143 (18) | 996 (8) |
| 40–59 | 2307 (28) | 896 (43) | 903 (51) | 330 (42) | 4436 (35) | |
| 60–79 | 5022 (61) | 987 (48) | 483 (27) | 307 (39) | 6799 (53) | |
| ≥80 | 490 (6) | 42 (2) | 11 (1) | 15 (2) | 558 (4) | |
| From the questionnaire: self-reported characteristics | ||||||
| Lives alone, n (%) | Yes | 1652 (20) | 356 (17) | 281 (16) | 133 (17) | 2422 (19) |
| Highest education†, n (%) | Lower education | 4415 (54) | 1116 (54) | 829 (47) | 355 (45) | 6715 (53) |
| Medium/long | 3696 (45) | 942 (46) | 920 (52) | 438 (55) | 5996 (47) | |
| Occupational status†, n (%) | Working | 3281 (40) | 1104 (53) | 1229 (70) | 462 (58) | 6076 (48) |
| Self-reported comorbidities, >1 answer allowed, n (%) | Lung disease, asthma | 1019 (12) | 213 (10) | 165 (9) | 88 (11) | 1485 (12) |
| Diabetes | 603 (7) | 204 (10) | 84 (5) | 44 (6) | 935 (7) | |
| Heart disease | 921 (11) | 225 (11) | 119 (7) | 76 (10) | 1341 (10) | |
| Cancer | 208 (3) | 33 (2) | 23 (1) | 12 (2) | 276 (2) | |
| Hypertension | 2778 (34) | 751 (36) | 398 (23) | 238 (30) | 4165 (33) | |
| Obesity | 703 (9) | 297 (14) | 154 (9) | 64 (8) | 1218 (10) | |
| Psychiatric/depression | 467 (6) | 181 (9) | 131 (7) | 68 (9) | 847 (7) | |
| Other | 2167 (27) | 585 (28) | 495 (28) | 277 (35) | 3424 (27) | |
| Number of self-reported comorbidities | 0 | 2699 (33) | 581 (28) | 679 (39) | 245 (31) | 4204 (33) |
| 1 | 2860 (35) | 708 (34) | 584 (33) | 257 (32) | 4409 (34) | |
| ≥2 | 2123 (26) | 640 (31) | 362 (21) | 226 (28) | 3351 (26) | |
| Pregnancy, n | Yes | 17 (0) | 1 (0) | 12 (1) | 7 (1) | 37 (0) |
| PASS, n (%) | Yes | 6119 (75) | 1414 (68) | 1217 (69) | 545 (69) | 9295 (73) |
| Current disease activity, median (IQR) | HAQ, median (IQR) | 0.50 (0.13–0.63) | 0.63 (0.13–0.75) | 0.50 (0.13–0.88) | 0.38 (0.0–0.88) | 0.50 (0.13–1.00) |
| Patient global, VAS, mm, median (IQR) | 28 (9–34) | 35 (13–40) | 31 (12–62) | 32 (10–58) | 29 (10–57) | |
| EQ-5D | 0.80 (0.72–0.86) | 0.77 (0.66–0.83) | 0.77 (0.69–0.83) | 0.79 (0.71–0.85) | 0.80 (0.71–0.86) | |
| Information captured from DANBIO: patient and disease characteristics‡ | ||||||
| Smoking status, n (%) | Current | 1447 (18) | 353 (17) | 354 (20) | 112 (14) | 2266 (18) |
| Previous | 2364 (29) | 621 (30) | 447 (25) | 173 (22) | 3605 (28) | |
| Never | 4279 (52) | 1073 (52) | 943 (54) | 474 (60) | 6769 (53) | |
| Year of diagnosis, n (%) | Before 2005 | 2587 (34) | 524 (25) | 450 (26) | 180 (23) | 3741 (29) |
| Current medication§, n (%) | bDMARD (±csDMARD) | 2572 (32) | 790 (38) | 1088 (62) | 202 (25) | 4652 (36) |
| csDMARD (no bDMARD) | 5014 (61) | 1052 (51) | 131 (7) | 377 (47) | 6574 (51) | |
Total n=12 789. Percentages are calculated among patients with available data (questionnaire: 93%–100% complete, previous information in DANBIO: 70%–100%, details in online supplemental table S2).
*Diagnoses in DANBIO include rheumatoid arthritis (sero-positive, sero-negative, unspecific, juvenile arthritis) (47% erosive disease, 65% anti-CCP positive, 58% IgM-RF positive)/axial spondyloarthritis (ankylosing spondylitis, undifferentiated spondyloarthritis, non-radiographic axial spondyloarthritis)/psoriatic arthritis (psoriatic arthritis/arthralgia)/other (systemic lupus erythematosus, Sjogren’s disease, chorioretinitis, reactive arthritis, ‘other’, missing).
†Status before corona lockdown. The categories include education: lower (Blue collar, short courses, no education), medium/long (2–3 years+3–4 years+>4 years, other). Occupational status: working (student, full-time employee, part-time employee, flex-job, self-employed, other), not working (unemployed, retired, sick-leave).
‡According to latest registration in DANBIO before 11 March 2020.
§bDMARD irrespective of concomitant csDMARD, csDMARD group exclude patients on concomitant bDMARD.
bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; EQ-5D, European Quality of life, 5 Dimensions; HAQ, health assessment questionnaire; PASS, patient acceptable symptom state; VAS, visual analogue scale.